138 related articles for article (PubMed ID: 30588016)
1. Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence.
Chen P; Chen F; Lei J; Zhou B
Onco Targets Ther; 2018; 11():9033-9047. PubMed ID: 30588016
[TBL] [Abstract][Full Text] [Related]
2. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
3. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.
Zhou G; Guo L; Xu J; Tang K; Chen J
Ther Adv Med Oncol; 2024; 16():17588359241227677. PubMed ID: 38304850
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
[TBL] [Abstract][Full Text] [Related]
7. [Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
He W; Cheng M
Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2591-2598. PubMed ID: 28840704
[TBL] [Abstract][Full Text] [Related]
8. The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis.
Zhao Z; Li L; Wang Z; Duan J; Bai H; Wang J
J Cancer; 2020; 11(11):3106-3113. PubMed ID: 32231715
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
10. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of Chinese herbal medicine as adjuvant treatment in advanced non-small cell lung cancer patients.
Wang LC; Chang YY; Lee IC; Kuo HC; Tsai MY
Complement Ther Med; 2020 Aug; 52():102472. PubMed ID: 32951722
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Wang C; Li Y; Ke L; Cao L; Fan P; Wu Z; Wu Q
J Cancer; 2019; 10(4):885-892. PubMed ID: 30854094
[No Abstract] [Full Text] [Related]
14. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Li X; Wang H; Lin W; Xu Q
Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
[TBL] [Abstract][Full Text] [Related]
18. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
